PGNX Progenics Pharmaceuticals Inc.

+0.1  (+3%)
Previous Close 3.6
Open 3.68
Price To Book 4.41
Market Cap 319,760,046
Shares 86,421,634
Volume 813,258
Short Ratio
Av. Daily Volume 825,490

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 completion of enrolment announced August 5, 2019 with data due by end of 2019.
Prostate cancer
FDA approval announced July 30, 2018.
Phase 3 trial met one of two co-primary endpoints.
Help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA)
Approved July 19 2016.
Chronic pain
Approved September 29, 2014.
Subcutaneous RELISTOR
Chronic pain
Abstract released at American Society of Clinical Oncology's 2014 Genitourinary Cancers Symposium Meeting in San Francisco in January 28 2014.
Cancer - metastatic castrate resistant prostate cancer (mCRPC).
Phase 2 initiation of dosing announced June 13, 2019.
Prostate Cancer

Latest News

  1. Edited Transcript of PGNX earnings conference call or presentation 9-Aug-19 12:30pm GMT
  2. Velan Highlights Progenics Pharmaceuticals' Continued Mismanagement Following Q2 2019 Earnings Results
  3. Progenics Pharmaceuticals (PGNX) Q2 2019 Earnings Call Transcript
  4. Could The Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Ownership Structure Tell Us Something Useful?
  5. Progenics (PGNX) Reports Q2 Loss, Tops Revenue Estimates
  6. Progenics Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update
  7. Progenics Pharmaceuticals Announces Additional Governance Enhancements
  8. CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA® (iobenguane I 131)
  9. Progenics Pharmaceuticals Completes Enrollment in Pivotal Phase 3 CONDOR Study of PyL for the Detection of Prostate Cancer
  10. Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results and Business Update Call for August 9
  11. Progenics Pharmaceuticals Announces Collaboration with Veterans Affairs on the AI Research Program for Medical Image Analysis
  12. Velan Announces Progenics Pharmaceuticals Stockholders Support its Campaign for Change at Progenics' 2019 Annual Meeting
  13. Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets
  14. Progenics Announces Preliminary Voting Results of Annual Meeting of Shareholders
  15. Progenics Urges Shareholders to Vote Today “FOR” the Highly Qualified Director Candidates on the WHITE Proxy Card
  16. Velan Reminds Stockholders to Follow ISS' Recommendation by Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley and Michael Kishbauch
  17. Progenics Pharmaceuticals Strengthens Management Team with Appointment of Huw Jones as Vice President, Commercial
  18. Here’s What Hedge Funds Think About Progenics Pharmaceuticals, Inc. (PGNX)
  19. Velan Urges Stockholders To Follow ISS' Recommendation By Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley And Michael Kishbauch